These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 37987318)
21. Clinical pharmacology of emicizumab for the treatment of hemophilia A. Yoneyama K; Schmitt C; Portron A; Kiialainen A; Kotani N; Jaminion F; Retout S; Adamkewicz JI Expert Rev Clin Pharmacol; 2023; 16(9):775-790. PubMed ID: 37529848 [TBL] [Abstract][Full Text] [Related]
22. Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study (HAVEN 5). Yang R; Wang S; Wang X; Sun J; Chuansumrit A; Zhou J; Schmitt C; Hsu W; Xu J; Li L; Chang T; Zhao X Res Pract Thromb Haemost; 2022 Feb; 6(2):e12670. PubMed ID: 35284778 [TBL] [Abstract][Full Text] [Related]
23. Effectiveness of emicizumab in preventing bleeding events in severe and moderate hemophilia A: A single-center experience in Bangladesh. Tory SS; Ghosh S; Nazneen H; Farhad N; Islam S; Hasan MJ; Biswas AR EJHaem; 2024 Feb; 5(1):39-46. PubMed ID: 38406515 [TBL] [Abstract][Full Text] [Related]
24. The efficacy of the entire-vial dosing of emicizumab: Real-world evidence on plasma concentrations, bleeds, and drug waste. Donners AAMT; van der Zwet K; Rademaker CMA; Egberts TCG; Schutgens REG; Fischer K Res Pract Thromb Haemost; 2023 Feb; 7(2):100074. PubMed ID: 36915864 [TBL] [Abstract][Full Text] [Related]
25. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Reyes A; Révil C; Niggli M; Chebon S; Schlagmüller S; Flacke JP; Zortel M; Paz-Priel I; Asikanius E; Hampton R; Mahajan A; Schmidt E; Edwards SC Curr Med Res Opin; 2019 Dec; 35(12):2079-2087. PubMed ID: 31355677 [No Abstract] [Full Text] [Related]
26. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963 [TBL] [Abstract][Full Text] [Related]
27. Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors. Kempton C; Trask P; Parnes A; Niggli M; Campinha-Bacote A; U Callaghan M; O'Connell N; Paz-Priel I; Mahlangu JN Haemophilia; 2021 Mar; 27(2):221-228. PubMed ID: 33506955 [TBL] [Abstract][Full Text] [Related]
28. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort. Barg AA; Avishai E; Budnik I; Levy-Mendelovich S; Barazani TB; Kenet G; Livnat T Pediatr Blood Cancer; 2019 Nov; 66(11):e27886. PubMed ID: 31348595 [TBL] [Abstract][Full Text] [Related]
29. Emicizumab dose up-titration in case of suboptimal bleeding control in people with haemophilia A. Schmitt C; Mancuso ME; Chang T; Podolak-Dawidziak M; Petry C; Sidonio R; Yoneyama K; Key NS; Niggli M; Lehle M; Peyvandi F; Oldenburg J Haemophilia; 2023 Jan; 29(1):90-99. PubMed ID: 36271487 [TBL] [Abstract][Full Text] [Related]
30. Expert opinion paper on the treatment of hemophilia a with emicizumab. López-Jaime FJ; Benítez O; Díaz Jordán BL; Montaño A; Coll J; Quintana París L; Gómez-Del Castillo Solano MDC Hematology; 2023 Dec; 28(1):2166334. PubMed ID: 36636993 [TBL] [Abstract][Full Text] [Related]
31. Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumab. Bou-Jaoudeh M; Mimoun A; Delignat S; Peyron I; Capdevila L; Daventure V; Deligne C; Dimitrov JD; Christophe OD; Denis CV; Lenting PJ; Proulle V; Lacroix-Desmazes S J Thromb Haemost; 2023 Oct; 21(10):2776-2783. PubMed ID: 37473843 [TBL] [Abstract][Full Text] [Related]
32. Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single-center report. Warren BB; Chan A; Manco-Johnson M; Branchford BR; Buckner TW; Moyer G; Gibson E; Thornhill D; Wang M; Ng CJ Res Pract Thromb Haemost; 2021 Jul; 5(5):e12571. PubMed ID: 34377887 [TBL] [Abstract][Full Text] [Related]
33. Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis. Mizumachi K; Tsumura Y; Nakajima Y; Koh K; Nogami K Int J Hematol; 2021 Jun; 113(6):930-935. PubMed ID: 33566316 [TBL] [Abstract][Full Text] [Related]
34. Real world impact of emicizumab & immunosuppression on Acquired Hemophilia A: A Multicenter US Cohort. Poston JN; Bryan C; von Drygalski A; Al Banaa K; Zhou JY; Parnes A; Chen EC; Khan O; Ellsworth P; Cafuir L; Walsh C; Escobar MA; Wu JF; Malec LM; Kessler CM; Janbain M; Kruse-Jarres R Blood Adv; 2024 Sep; ():. PubMed ID: 39361769 [TBL] [Abstract][Full Text] [Related]
35. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Négrier C; Mahlangu J; Lehle M; Chowdary P; Catalani O; Bernardi RJ; Jiménez-Yuste V; Beckermann BM; Schmitt C; Ventriglia G; Windyga J; d'Oiron R; Moorehead P; Koparkar S; Teodoro V; Shapiro AD; Oldenburg J; Hermans C Lancet Haematol; 2023 Mar; 10(3):e168-e177. PubMed ID: 36716761 [TBL] [Abstract][Full Text] [Related]
36. AOZORA: long-term safety and joint health in paediatric persons with haemophilia A without factor VIII inhibitors receiving emicizumab - protocol for a multicentre, open-label, phase IV clinical study. Shima M; Takedani H; Kitsukawa K; Taki M; Ishiguro A; Nagao A; Yamaguchi-Suita H; Kyogoku Y; Yoshida S; Nogami K BMJ Open; 2022 Jun; 12(6):e059667. PubMed ID: 35697445 [TBL] [Abstract][Full Text] [Related]
37. Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures. McCary I; Guelcher C; Kuhn J; Butler R; Massey G; Guerrera MF; Ballester L; Raffini L Haemophilia; 2020 Jul; 26(4):631-636. PubMed ID: 32311809 [TBL] [Abstract][Full Text] [Related]
38. Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays. Kizilocak H; Yukhtman CL; Marquez-Casas E; Lee J; Donkin J; Young G Ther Adv Hematol; 2019; 10():2040620719860025. PubMed ID: 31275538 [TBL] [Abstract][Full Text] [Related]
39. Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial. Ogiwara K; Taki M; Suzuki T; Takedani H; Matsushita T; Amano K; Matsumoto M; Nishio K; Shima M; Kasahara M; Nogami K BMJ Open; 2022 Feb; 12(2):e056922. PubMed ID: 35177463 [TBL] [Abstract][Full Text] [Related]
40. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Oldenburg J; Mahlangu JN; Bujan W; Trask P; Callaghan MU; Young G; Asikanius E; Peyvandi F; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Xu J; Windyga J; Shima M; von Mackensen S Haemophilia; 2019 Jan; 25(1):33-44. PubMed ID: 30427582 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]